{
    "clinical_study": {
        "@rank": "62108", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Subjects", 
                "description": "(no auto-immune disease)"
            }, 
            {
                "arm_group_label": "Subjects with Crohn's Disease"
            }, 
            {
                "arm_group_label": "Subjects with Rheumatoid Arthritis"
            }, 
            {
                "arm_group_label": "Subjects with Type 1 diabetes"
            }, 
            {
                "arm_group_label": "Subjects with Multiple Sclerosis (MS)"
            }, 
            {
                "arm_group_label": "Subjects with Psoriasis"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The study aims to establish whether defects in immune cell function are shared across\n      multiple autoimmune diseases and whether those problems match to similar genes in the cells.\n      We will look at immune cells from each subject and match the differences to types of immune\n      cells known to cause autoimmune diseases. We will also investigate a particular disease\n      pathway - the IL23R signaling cascade.  We want to establish whether alterations to this\n      function are present in multiple diseases."
        }, 
        "brief_title": "T and B Cell Responses Across Autoimmune Diseases", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 1 Diabetes Mellitus", 
            "Multiple Sclerosis", 
            "Arthritis, Rheumatoid", 
            "Crohn Disease", 
            "Psoriasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Autoimmune Diseases", 
                "Crohn Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Multiple Sclerosis", 
                "Psoriasis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject or subject's parent or legal guardian has provided written informed consent.\n\n          2. For healthy donors:\n\n             a. Healthy individuals between 18 and 60 years of age, inclusive.\n\n          3. For all subjects with an autoimmune disease:\n\n               1. Adults between 18 and 60 years, inclusive diagnosed with or suspected of having\n                  one of the following five diseases: adult forms of rheumatoid arthritis (RA),\n                  type I diabetes (T1D), multiple sclerosis (MS), Crohn's disease (CD), Psoriasis\n                  (Ps)\n\n               2. Or Children from 8 years up to 18 years inclusive diagnosed with or suspected of\n                  having type I diabetes (TID) or Crohn's disease (CD)\n\n               3. Treatment na\u00efve except for prednisone (or equivalent corticosteroid) \u2264 10mg/day\n\n          4. For subjects diagnosed with type 1diabetes:\n\n               1. Clinical diagnosis or suspected diagnosis of type 1 diabetes\n\n               2. Positive per standard clinical titer levels for anti-insulin antibodies if\n                  within 10 days of diagnosis; else one of anti-GAD65, anti-ICA512/IA2 or\n                  anti-ZnT8 antibodies\n\n               3. Minimum body weight 17kg\n\n               4. Disease duration within 1 year\n\n          5. For subjects diagnosed with multiple sclerosis:\n\n               1. EDSS 0-5\n\n               2. Diagnosis or suspected diagnosis of MS as per Polman et al. Annals of Neurology\n                  2010\n\n               3. Disease duration within 1 year\n\n          6. For subjects diagnosed with rheumatoid arthritis\n\n               1. Diagnosis or suspected diagnosis of RA (2010 ACR criteria)\n\n               2. Anti-CCP antibody positive\n\n               3. Disease duration within 1 year\n\n          7. For subjects diagnosed with Crohn's disease:\n\n               1. Clinical diagnosis or suspected diagnosis of Crohn's confirmed by endoscopy\n\n               2. Disease duration within 1 year\n\n               3. Minimum body weight 17 kg\n\n          8. For subjects diagnosed with psoriasis:\n\n               1. Psoriasis diagnosis by a dermatologist\n\n               2. Disease duration within 1 year\n\n               3. At least two psoriatic plaques or a single plaque occupying >1% of total body\n                  surface outside scalp\n\n        Exclusion Criteria:\n\n          1. For healthy donors:\n\n               1. Individuals who are unable or unwilling to donate blood samples\n\n               2. Individuals with self-reported chronic metabolic diseases such as type 2\n                  diabetes, impaired glucose tolerance or morbid obesity;\n\n               3. Individuals with self-reported infectious diseases such as HIV/AIDS, hepatitis B\n                  or C;\n\n               4. Individuals with self-reported immune-mediated diseases such as multiple\n                  sclerosis, type 1 diabetes, primary immunodeficiency,\n\n               5. Individuals with self-reported current or prior history of malignancy\n\n               6. Individuals who are currently pregnant (self-report).\n\n               7. Corticosteroid therapy equivalent to \u2265 10 mg/day of prednisone within the last 4\n                  weeks\n\n               8. Immunosuppressive therapy at any time prior to enrollment (such as\n                  Cyclophosphamide, Mitoxantrone, Imuran, Cellcept, Methotrexate, Rituximab,\n                  Alemtuzumab)\n\n          2. For all subjects with an autoimmune disease:\n\n               1. Pregnant patients\n\n               2. Pediatric patients unable to donate at least 51 mL of blood per NIH guidelines\n                  (no more than 5 mL/kg in a single day and no more than 9.5 mL/kg over any 8 week\n                  period)\n\n               3. Patients with current substance abuse or alcoholism (self-report)\n\n               4. Patients diagnosed with more than one autoimmune and/or inflammatory disease,\n                  asthma is permissible\n\n               5. Current acute infection (respiratory or others), chronic infection (such as HIV,\n                  Hepatitis B or C)\n\n               6. Corticosteroid therapy equivalent to > 10 mg/day of prednisone within the last 4\n                  weeks\n\n               7. Immunomodulatory therapies within the last 12 months (such as Interferon,\n                  Glatiramer Acetate, Natalizumab, Fingolimod)\n\n               8. Immunosuppressive medication at any time prior to enrollment (such as\n                  Cyclophosphamide, Mitoxantrone, Imuran, Cellcept, Methotrexate, Rituximab,\n                  Alemtuzumab)\n\n               9. Any prior or current Anti-tumor necrosis factor (anti-TNF) treatments\n\n              10. Any prior or current use of experimental drugs tested in Phase I, II, or III\n                  trials\n\n          3. Diagnosis of ulcerative colitis or indeterminate colitis\n\n          4. Pustular psoriasis, isolated palmoplantar psoriasis, isolated inverse psoriasis and\n             isolated sebopsoriasis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "8 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants who are healthy or have a confirmed or suspected diagnosis of type 1diabetes\n        (T1D), multiple sclerosis (MS), psoriasis (Ps), Crohn's disease (CD), or rheumatoid\n        arthritis (RA). will be asked to donate a blood sample. Around 40 participants per disease\n        group with confirmed diagnosis will be analyzed. No follow-ups are planned."
            }
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947036", 
            "org_study_id": "DAIT SRA01"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Arpita Singh", 
                    "phone": "203-737-7453"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Yale University"
                }, 
                "investigator": {
                    "last_name": "Chris Cotsapas, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jennifer.scantlin@emory.edu", 
                    "last_name": "Jennifer Scantlin", 
                    "phone": "404-712-2943"
                }, 
                "contact_backup": {
                    "email": "jkozars@emory.edu", 
                    "last_name": "Julie F. Kozarsky"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }, 
                "investigator": {
                    "last_name": "Ignacio Sanz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "michelleg_smith@urmc.rochester.edu", 
                    "last_name": "Michelle G. Smith", 
                    "phone": "585-275-1634"
                }, 
                "contact_backup": {
                    "email": "barbara_johnson@urmc.rochester.edu", 
                    "last_name": "Barbara Johnson, RN", 
                    "phone": "585 276 3513"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester"
                }, 
                "investigator": [
                    {
                        "last_name": "R. John Looney, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Nicholas Jospe, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Micki-Moore@omrf.org", 
                    "last_name": "Micki Moore"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City,", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Oklahoma Medical Research Foundation"
                }, 
                "investigator": {
                    "last_name": "Judith James, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jeaninba@baylorhealth.edu", 
                    "last_name": "Jeanine Baisch", 
                    "phone": "214-820-7454"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75204"
                    }, 
                    "name": "Baylor Institute of Immunology Research"
                }, 
                "investigator": {
                    "last_name": "Virginia Pascual, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "6", 
        "overall_contact": {
            "email": "arpita.singh@yale.edu", 
            "last_name": "Arpita Singh", 
            "phone": "203-737-7453"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Chris Cotsapas, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The study aims to establish whether defects in T and B cell function are shared across multiple immune-mediated diseases and whether these are driven by shared genetic risk variants.", 
            "measure": "Incidence of shared defects in T and B cell function", 
            "safety_issue": "No", 
            "time_frame": "At time of blood sampling"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947036"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}